Study Details

Back to Search Results

A study to evaluate safety and efficacy of ASP015K in patients with rheumatoid arthritis (RA) who had an inadequate response to DMARDs

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT02308163

Astellas Study ID

The unique identification code given by the study sponsor.

015K-CL-RAJ3

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Rheumatoid Arthritis

Phase

These clinical trials are done to confirm that an experimental treatment helps participants who have a specific condition. These clinical trials often compare the experimental treatment to another treatment or, if appropriate, a placebo.

Phase 3

Age

20 years - N/A

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Aug 2014 - Nov 2017

Masking

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Enrollment number

509

Phase 3 Study of ASP015K – A randomized, double-blind, placebo-controlled confirmatory study of the safety and efficacy of ASP015K in patients with rheumatoid arthritis who had an inadequate response to DMARDs

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A study to evaluate safety and efficacy of ASP015K in patients with rheumatoid arthritis (RA) who had an inadequate response to DMARDs? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

JP00163

Higashihiroshima, Japan

JP00125

Kushiro, Japan

KR00506

Incheon, Republic of Korea

JP00059

Fukuoka, Japan

JP00060

Kawagoe, Japan

JP00112

Nagasaki, Japan

JP00011

Hannan, Japan

JP00038

Sapporo, Japan

JP00035

Fukuoka, Japan

JP00161

Kawagoe, Japan

JP00099

Chiyoda, Japan

JP00133

Kakegawa, Japan

JP00041

Kato, Japan

JP00078

Kawachinagano, Japan

JP00106

Kurume, Japan

JP00130

Nagoya, Japan

KR00509

Seoul, Republic of Korea

JP00136

Itami, Japan

JP00162

Isehaya, Japan

TW00703

Taoyuan, Taiwan, Province of China

KR00510

Daegu, Republic of Korea

JP00022

Kumamoto, Japan

JP00063

Hachioji, Japan

KR00501

Seoul, Republic of Korea

JP00007

Hiki, Japan

JP00036

Sendai, Japan

JP00119

Kitakyushu, Japan

JP00048

Kawasaki, Japan

KR00511

Seoul, Republic of Korea

JP00094

Kashihara, Japan

JP00008

Tokorozawa, Japan

JP00151

Sendai, Japan

JP00024

Bunkyo, Japan

KR00504

Daegu, Republic of Korea

JP00155

Nishimuro, Japan

JP00043

Bunkyo, Japan

JP00137

Sakai, Japan

TW00709

Kaohsiung, Taiwan, Province of China

JP00109

Nagoya, Japan

JP00057

Tamana, Japan

TW00708

Kaohsiung, Taiwan, Province of China

JP00135

Shizuoka, Japan

JP00115

Narashino, Japan

JP00055

Hiroshima, Japan

JP00114

Sapporo, Japan

JP00102

Kamagaya, Japan

JP00156

Toyota, Japan

JP00134

Higashiosaka, Japan

JP00027

Sendai, Japan

JP00077

Kanuma, Japan

JP00067

Fukuoka, Japan

JP00065

Kagoshima, Japan

JP00089

Shizuoka, Japan

JP00082

Iruma, Japan

JP00108

Toyohashi, Japan

JP00126

Gyoda, Japan

JP00093

Kochi, Japan

JP00001

Sapporo, Japan

KR00508

Jeonju, Republic of Korea

TW00711

Taipei, Taiwan, Province of China

JP00073

Koga, Japan

JP00023

Miyagi, Japan

JP00148

Ota, Japan

JP00037

Nagoya, Japan

JP00075

Ureshino, Japan

JP00080

Nagano, Japan

JP00098

Nagasaki, Japan

JP00154

Kobe, Japan

JP00142

Chuo, Japan

JP00064

Beppu, Japan

JP00088

Kida, Japan

JP00069

Himeji, Japan

JP00120

Iizuka, Japan

JP00070

Suita, Japan

JP00004

Sendai, Japan

TW00704

Taichung, Taiwan, Province of China

JP00025

Nagaoka, Japan

TW00710

Taichung, Taiwan, Province of China

JP00139

Toyama, Japan

JP00153

Sasebo, Japan

JP00101

Omura, Japan

JP00018

Fukuoka, Japan

JP00031

Sapporo, Japan

KR00502

Seoul, Republic of Korea

JP00147

Nagasaki, Japan

JP00144

Shibata, Japan

TW00712

Tainan, Taiwan, Province of China

JP00042

Kobe, Japan

JP00107

Hitachi, Japan

JP00086

Suita, Japan

JP00158

Sapporo, Japan

JP00026

Asahikawa, Japan

JP00010

Takaoka, Japan

JP00002

Sapporo, Japan

JP00017

Oita, Japan

JP00127

Matsudo, Japan

JP00020

Fukuoka, Japan

JP00066

Okazaki, Japan

JP00123

Kyoto, Japan

JP00033

Takasaki, Japan

JP00090

Hakodate, Japan

JP00117

Nishinomiya, Japan

KR00503

Seoul, Republic of Korea

TW00701

Taipei, Taiwan, Province of China

JP00141

Sagamihara, Japan

JP00118

Okayama, Japan

JP00049

Morioka, Japan

JP00040

Kitakyushu, Japan

JP00050

Hyuga, Japan

JP00076

Fukuoka, Japan

JP00100

Setagaya, Japan

JP00003

Sapporo, Japan

JP00143

Bunkyo, Japan

JP00052

Sayama, Japan

JP00145

Shimotsuke, Japan

JP00164

Fukuoka, Japan

JP00032

Shinjuku, Japan

JP00047

Shunan, Japan

JP00113

Kakogawa, Japan

JP00062

Kawaguchi, Japan

JP00159

Kyoto, Japan

JP00085

Kyoto, Japan

JP00056

Akashi, Japan

JP00058

Kawasaki, Japan

TW00702

Taipei, Taiwan, Province of China

JP00016

Hiroshima, Japan

JP00110

Kasuga, Japan

JP00054

Mito, Japan

JP00140

Toyoake, Japan

JP00061

Toyonaka, Japan

JP00083

Meguro, Japan

JP00053

Kiyose, Japan

JP00150

Osaka, Japan

KR00507

Suwon, Republic of Korea

JP00103

Omura, Japan

JP00131

Fukuoka, Japan

JP00095

Chiyoda, Japan

JP00084

Isehara, Japan

JP00015

Hiroshima, Japan

JP00074

Kagoshima, Japan

JP00092

Kobe, Japan

TW00705

Taichung, Taiwan, Province of China

JP00051

Setouchi, Japan

JP00046

Kumamoto, Japan

KR00505

Gwangju, Republic of Korea

JP00138

Yotsukaido, Japan

JP00014

Hiroshima, Japan

JP00146

Suita, Japan

JP00122

Miyazaki, Japan

JP00071

Kurume, Japan

JP00104

Shimonoseki, Japan

JP00157

Osaka, Japan

JP00096

Yokohama, Japan

JP00152

Bunkyo, Japan

JP00149

Bunkyo, Japan

JP00105

Sendai, Japan

JP00013

Hiroshima, Japan

JP00128

Yokosuka, Japan

JP00068

Yatomi, Japan

JP00072

Meguro, Japan

JP00097

Kurume, Japan

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo